5 recruiting. 5 Phase 2, 5 Phase 3.
By phase and status
Follow Malignant Neoplasm: new trials by email Literature Review of Malignant Neoplasm trials Research Report on Malignant Neoplasm
Trials (filtered) newest first · largest first
All 5 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
Dabrafenib, Trametinib - Haematological Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | 30 | 2026-04-01 | 2026-08-17 |
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
Entrectinib - Haematological Malignancy, Malignancy | Phase 2 / Phase 3 | Recruiting | 30 | 2025-11-30 | 2025-11-24 |
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
Capmatinib - Solid Tumour, Haematological Malignancy | Phase 2 / Phase 3 | Recruiting | 30 | 2024-11-19 | 2025-11-24 |
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
Alectinib - Haematological Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | 30 | 2023-12-18 | 2025-11-24 |
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
Atezolizumab - Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | 30 | 2023-10-25 | 2025-11-24 |
Narrower conditions
Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms by Site (5) · Hematologic Neoplasms (4) · Lymphoproliferative Disorders (4) · Glioma (3) · Colorectal Neoplasms (2) · Melanoma (2) · Neuroblastoma (2) · Brain Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Endometrial Neoplasms (1) · Erdheim-Chester Disease (1) · Gastrointestinal Neoplasms (1)
Broader conditions
Hemic and Lymphatic Diseases (5) · Neoplasms, Germ Cell and Embryonal (5) · Neoplasms, Nerve Tissue (5) · Neuroectodermal Tumors (5) · Hematologic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Neoplasms, Glandular and Epithelial (4) · Neoplasms, Neuroepithelial (4) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Gastrointestinal Diseases (3)
Interventions
alectinib (1) · atezolizumab (1) · capmatinib (1) · dabrafenib (1) · entrectinib (1) · trametinib (1)
Sponsors
Cancer Research UK (5)
Countries
United Kingdom (5)
Top investigators
Matthew Krebs, Dr (4) · Matthew Krebs (1)
Results publications
PMID 38662981